Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Northwest Biotherapeutics, Inc.: Strengths and Weaknesses

Highlights: Northwest Biotherapeutics, Inc.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Rating Financials

Northwest Biotherapeutics, Inc. SectorGermany

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Northwest Biotherapeutics, Inc. SectorGermany

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Northwest Biotherapeutics, Inc. SectorGermany

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

-

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Northwest Biotherapeutics, Inc. SectorGermany

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

Northwest Biotherapeutics, Inc. SectorGermany

Financial revisions

-

Revenue revisions (1 year)

-

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

-

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
299M - - - - - -
53.54B
AAA
54.18B
A
23.66B -
A
- -
22.78B - - - -
19.54B
AAA
17.82B
A
16.01B
AA
15.37B -
AA
- -
14.09B
BB
Average 23.73B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. NWBO Stock
  4. NBYB Stock
  5. Ratings Northwest Biotherapeutics, Inc.